Text Size

MRI in Staging Ovarian Cancer Using MRI Contrast Agent

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2007 by University of Aarhus.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
University of Aarhus
ClinicalTrials.gov Identifier:
NCT00463996
First received: April 18, 2007
Last updated: NA
Last verified: April 2007
History: No changes posted
  Purpose

Can MRI be used to stage ovarian cancer?


Condition
Ovarian Cancer

Study Type: Observational
Study Design: Observational Model: Case Control
Primary Purpose: Screening
Time Perspective: Longitudinal
Time Perspective: Prospective
Official Title: Værdien af MRI Til Staging af c.Ovarii-et Prospektivt Studie

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by University of Aarhus:

Estimated Enrollment: 50
Study Start Date: April 2007
Estimated Study Completion Date: April 2008
Detailed Description:

Staging of ovarian cancer can best be performed with CT or MRI compared to ultrasound. Studies have shown an increase in pos. predictive value by adding contrast i.v. to the MR-examination protocol. We compare staging of ovarian cancer by 1.MRI without contrast (standard method) to 2.MRI with contrast agent i.v. (new method)in the same patient. Golden standard are findings at operation.

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • suspicion of ovarian cancer

Exclusion Criteria:

  • recurrence of disease
  • contraindication to MRI, contrast agent
  • inoperable patients for other reasons
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00463996

Contacts
Contact: Liselotte Ibsen, doc +4589495201
Contact: Erik Lundorf, consultant +4589495251 elu@sks.aaa.dk

Sponsors and Collaborators
University of Aarhus
Investigators
Principal Investigator: Liselotte Ibsen, doc Aarhus University Hospital, BDA, Skejby
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00463996     History of Changes
Other Study ID Numbers: MR-Center-001
Study First Received: April 18, 2007
Last Updated: April 18, 2007
Health Authority: Denmark: Ethics Committee

Keywords provided by University of Aarhus:
Ovarian cancer
MRI
Contrast agent

Additional relevant MeSH terms:
Ovarian Neoplasms
Endocrine Gland Neoplasms
Neoplasms by Site
Neoplasms
Ovarian Diseases
Adnexal Diseases
 Genital Diseases, Female
Genital Neoplasms, Female
Urogenital Neoplasms
Endocrine System Diseases
Gonadal Disorders

ClinicalTrials.gov processed this record on May 22, 2013